ArticleFrontiers in molecular biosciences2026
BoNT/E-associated protein disrupts intestinal epithelial barrier integrity to facilitate transcytosis.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial and endothelial barriers play essential roles in maintaining compartmentalization within the body through specialized intercellular junctional complexes. Botulinum neurotoxin type E (BoNT/E), a ~150 kDa protein toxin produced by Methods: P80 was purified from the BoNT/E progenitor toxin complex and characterized using circular dichroism spectroscopy and thermal denaturation analysis. Its biological activity was evaluated using hemagglutination assays, cytotoxicity studies, confocal microscopy, atomic force microscopy (AFM), immunofluorescence imaging, tight junction protein analysis, and transcytosis assays in Caco-2 and HT-29 intestinal epithelial cell models. Results: Structural analyses revealed that P80 is a stable, predominantly α-helical protein with a well-defined tertiary structure. P80 exhibited no detectable hemagglutination activity and showed minimal cytotoxicity toward intestinal epithelial cells. Cellular studies demonstrated that P80 interacts with epithelial monolayers, induces actin cytoskeletal remodeling, increases claudin-1 phosphorylation, and alters tight junction organization. AFM and confocal microscopy revealed changes consistent with transient modulation of epithelial barrier integrity. Functional transcytosis studies showed that P80 significantly enhanced the transport of co-incubated macromolecular cargo across polarized Caco-2 monolayers, resulting in approximately a fivefold increase in translocation compared with untreated controls. Discussion: These findings demonstrate that P80 functions as a non-toxic modulator of epithelial barrier permeability capable of enhancing paracellular transport of large biomolecules. Unlike classical hemagglutinin-associated neurotoxin proteins, P80 lacks hemagglutination activity while retaining the ability to reversibly alter tight junction dynamics. The results suggest that P80 contributes to BoNT/E intestinal absorption and may serve as a promising bioenhancer for improving mucosal delivery of therapeutic proteins and other hydrophilic macromolecules. Further mechanistic and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.